2024-11-21 |
[Comment] A new seed amplification assay to diagnose multiple system atrophy |
James A Wiseman, Glenda M Halliday, Birger Victor Dieriks |
|
2024-11-21 |
[Comment] The amyloid clock: mapping Alzheimer's disease in Down syndrome |
Michael S Rafii |
|
2024-11-21 |
[Comment] REM sleep behaviour disorder and α-synuclein |
Bradley F Boeve, Tanis J Ferman |
|
2024-11-21 |
[Comment] Ischaemic brain oedema remains a major unmet need |
Alejandro A Rabinstein |
|
2024-11-21 |
[Correspondence] Effects of climate change on the brain: an environmental neurology perspective – Authors’ reply |
Sanjay M Sisodiya, Mark A Maslin, Marina Romanello, Michael G Hanna |
|
2024-11-21 |
[Articles] Post-mortem neuropathology of idiopathic rapid eye movement sleep behaviour disorder: a case series |
Gerard Mayà, Alex Iranzo, Carles Gaig, Raquel Sánchez-Valle, Monica Serradell, Laura Molina-Porcel, Joan Santamaria, Ellen Gelpi, Iban Aldecoa |
|
2024-11-21 |
[In Context] Christian Endisch |
|
|
2024-11-21 |
[In Context] 200 years since the death of James Parkinson |
Marcus V Della Coletta, Helio A G Teive, Andrew Lees |
|
2024-11-21 |
[Comment] Globalisation of the pharmacological treatment of migraine |
Massimo Leone |
|
2024-11-21 |
[In Context] The legacy of Egas Moniz |
Maria Francisca Rocha, Rosa Maria Rodrigues, Arpan R Mehta |
|
2024-11-21 |
[Articles] Intravenous glibenclamide for cerebral oedema after large hemispheric stroke (CHARM): a phase 3, double-blind, placebo-controlled, randomised trial |
Kevin N Sheth, Gregory W Albers, Jeffrey L Saver, Bruce C V Campbell, Bradley J Molyneaux, H E Hinson, Charlotte Cordonnier, Thorsten Steiner, Kazunori Toyoda, Max Wintermark, Ross Littauer, Jessica Collins, Nisha Lucas, Raul G Nogueira, J Marc Simard, Mi |
|
2024-11-21 |
[Articles] Sensitivity and specificity of a seed amplification assay for diagnosis of multiple system atrophy: a multicentre cohort study |
Yihua Ma, Carly M Farris, Sandrina Weber, Sebastian Schade, Hieu Nguyen, Alexandra Pérez-Soriano, Darly M Giraldo, Manel Fernández, Marta Soto, Ana Cámara, Celia Painous, Esteban Muñoz, Francesc Valldeoriola, Maria J Martí, Jordi Clarimon, Pekka Kallunki, |
|
2024-11-21 |
[Correspondence] Effects of climate change on the brain: an environmental neurology perspective |
Jacques Reis, Alain Buguet, Manny W Radomski, Gustavo C Román, Peter S Spencer |
|
2024-11-21 |
[In Context] Monitoring brainwaves while gallery visitors view artworks |
Peter Ranscombe |
|
2024-11-21 |
[Correspondence] Surgical treatment for chronic subdural haematoma |
Liang Wu, Guoyi Gao, Weiming Liu |
|
2024-11-21 |
[Correspondence] Surgical treatment for chronic subdural haematoma –Authors’ reply |
Mads Hjortdal Grønhøj, Frantz Rom Poulsen |
|
2024-11-21 |
[Correspondence] Surgical treatment for chronic subdural haematoma |
Haibo Teng, Zhiyong Liu, Jianguo Xu |
|
2024-11-21 |
[Correspondence] Surgical treatment for chronic subdural haematoma |
Muhammed Amir Essibayi, Deepak Khatri, David Altschul |
|
2024-11-21 |
[Comment] PACAP pathway: a new frontier in migraine prevention |
Mario Fernando Prieto Peres |
|
2024-11-21 |
[In Context] The elusive foundations of creativity |
Rui Araújo |
|
2024-11-21 |
[Review] Multiple system atrophy: advances in pathophysiology, diagnosis, and treatment |
Florian Krismer, Alessandra Fanciulli, Wassilios G Meissner, Elizabeth A Coon, Gregor K Wenning |
|
2024-11-21 |
[In Context] The woman who was not there |
Marco De Ambrogi |
|
2024-11-21 |
[Comment] Antiplatelet therapy after intracerebral haemorrhage |
Wendy C Ziai, Santosh B Murthy, Christopher P Kellner |
|
2024-11-21 |
[Articles] Safety and efficacy of early versus delayed acetylsalicylic acid after surgery for spontaneous intracerebral haemorrhage in China (E-start): a prospective, multicentre, open-label, blinded-endpoint, randomised trial |
Qingyuan Liu, Shaohua Mo, Jun Wu, Xianzeng Tong, Kaiwen Wang, Xu Chen, Shanwen Chen, Shuaiwei Guo, Xiong Li, Mingde Li, Lei Peng, Xinguo Sun, Yang Wang, Jianjun Sun, Jun Pu, Kaige Zheng, Jiaming Zhang, Yang Liu, Yi Yang, Zheng Wen, Xin Nie, Yinghe Feng, C |
|
2024-11-21 |
[Corrections] Correction to Lancet Neurol 2024; 23: 961–62 |
|
|
2024-11-21 |
[Articles] Timeline to symptomatic Alzheimer's disease in people with Down syndrome as assessed by amyloid-PET and tau-PET: a longitudinal cohort study |
Emily K Schworer, Matthew D Zammit, Jiebiao Wang, Benjamin L Handen, Tobey Betthauser, Charles M Laymon, Dana L Tudorascu, Annie D Cohen, Shahid H Zaman, Beau M Ances, Mark Mapstone, Elizabeth Head, Bradley T Christian, Sigan L Hartley, Alzheimer's Biomar |
|
2024-11-21 |
[In Context] Frank Longo: taking on Alzheimer's disease |
Henna Hundal |
|
2024-11-21 |
[Editorial] United action is needed to prioritise brain health |
The Lancet Neurology |
|
2024-11-21 |
[Personal View] Uncovering the genetic basis of Parkinson's disease globally: from discoveries to the clinic |
Shen-Yang Lim, Ai Huey Tan, Azlina Ahmad-Annuar, Njideka Ulunma Okubadejo, Katja Lohmann, Huw R Morris, Tzi Shin Toh, Yi Wen Tay, Lara M Lange, Sara Bandres-Ciga, Ignacio Mata, Jia Nee Foo, Esther Sammler, Joshua Chin Ern Ooi, Alastair J Noyce, Natascha B |
|
2024-11-21 |
[Comment] The global dimension of Parkinson's disease genetics |
Thomas Gasser |
|
2024-11-21 |
[Correspondence] The European expertise network for open microvascular surgery |
Victor Volovici, Marco Cenzato, Torstein R Meling, EXPERVASC |
|
2024-10-17 |
[Corrections] Correction to Lancet Neurol 2024; 23: 1086 |
|
|
2024-10-17 |
[Personal View] CNS disease associated with enhanced type I interferon signalling |
Yanick J Crow |
|
2024-10-17 |
[In Context] Rustam Al-Shahi Salman: balancing depth and breadth with intracerebral haemorrhage |
Jennifer Thorley |
|
2024-10-17 |
[Editorial] Dementia-related stigma is still pervasive |
The Lancet Neurology |
|
2024-10-17 |
[In Context] Supporting young carers across neurological disorders |
Melinda S Kavanaugh |
|
2024-10-17 |
[In Context] Head impacts in elite professional football: a growing concern |
Irina Martín-Izquierdo, Mónica Serradell, Bernat Nadal, Irene Madurga, Alex Iranzo |
|
2024-10-17 |
[Comment] Changing multiple-sclerosis-induced thoughts and behaviours |
Heleen Beckerman, Vincent de Groot |
|
2024-10-17 |
[Comment] A new era of drug discovery for amyotrophic lateral sclerosis |
Jinsy A Andrews |
|
2024-10-17 |
[Correspondence] Jules Froment's neurological statuettes |
Hugo Ardaillon, Mélia Virely, Peggy Leplat-Bonnevialle, Jérôme Honnorat, Stéphane Thobois |
|
2024-10-17 |
[Comment] A new standard for thrombolysis in acute ischaemic stroke |
Lina Palaiodimou, Georgios Tsivgoulis |
|
2024-10-17 |
[Correspondence] Changing the landscape of neurological education |
Lukas Sveikata, Indrit Bègue, Raphael Guzman, Luca Remonda, Claudio LA Bassetti |
|
2024-10-17 |
[Correspondence] Dealing with the reproducibility crisis in neuroscience from the grassroots |
Arpan R Mehta |
|
2024-10-17 |
[Articles] Comparative effectiveness of cognitive behavioural therapy, modafinil, and their combination for treating fatigue in multiple sclerosis (COMBO-MS): a randomised, statistician-blinded, parallel-arm trial |
Tiffany J Braley, Dawn M Ehde, Kevin N Alschuler, Roderick Little, Yee To Ng, Yuqi Zhai, Gloria von Geldern, Ronald D Chervin, Deirdre Conroy, Thomas R Valentine, Andrew R Romeo, Nicholas LaRocca, Maysa Hamade, Allison Jordan, Mini Singh, Benjamin M Segal |
|
2024-10-17 |
[Correspondence] Neurology crisis in Ethiopia: imbalances in training and retention |
Blen M Gebresilassie, James H Bower, Mehila Zebenigus |
|
2024-10-17 |
[Correspondence] Multidisciplinary care for rare neurological diseases in China |
Xin-Yuan Chen |
|
2024-10-17 |
[Comment] Type I interferonopathies with CNS symptoms |
Shyamala Mani, Angela M Kaindl |
|
2024-10-17 |
[Articles] Safety, tolerability, and efficacy of fasudil in amyotrophic lateral sclerosis (ROCK-ALS): a phase 2, randomised, double-blind, placebo-controlled trial |
Jan C Koch, Andreas Leha, Helen Bidner, Isabell Cordts, Johannes Dorst, René Günther, Daniel Zeller, Nathalie Braun, Moritz Metelmann, Philippe Corcia, Elisa De La Cruz, Patrick Weydt, Thomas Meyer, Julian Großkreutz, Marie-Hélène Soriani, Shahram Attaria |
|
2024-10-17 |
[Articles] Tenecteplase versus alteplase for acute stroke within 4·5 h of onset (ATTEST-2): a randomised, parallel group, open-label trial |
Keith W Muir, Gary A Ford, Ian Ford, Joanna M Wardlaw, Alex McConnachie, Nicola Greenlaw, Grant Mair, Nikola Sprigg, Christopher I Price, Mary Joan MacLeod, Sofia Dima, Marius Venter, Liqun Zhang, Eoin O’Brien, Ranjan Sanyal, John Reid, Laszlo K Sztriha, |
|
2024-10-17 |
[In Context] Andrea Schneider |
|
|
2024-10-17 |
[Articles] Safety and efficacy of memantine and trazodone versus placebo for motor neuron disease (MND SMART): stage two interim analysis from the first cycle of a phase 3, multiarm, multistage, randomised, adaptive platform trial |
Suvankar Pal, Jeremy Chataway, Robert Swingler, Malcolm R Macleod, Neil O Carragher, Giles Hardingham, Bhuvaneish Thangaraj Selvaraj, Colin Smith, Charis Wong, Judith Newton, Dawn Lyle, Amy Stenson, Rachel S Dakin, Amarachi Ihenacho, Shuna Colville, Arpan |
|
2024-10-17 |
[Articles] Safety and efficacy of evobrutinib in relapsing multiple sclerosis (evolutionRMS1 and evolutionRMS2): two multicentre, randomised, double-blind, active-controlled, phase 3 trials |
Xavier Montalban, Patrick Vermersch, Douglas L Arnold, Amit Bar-Or, Bruce A C Cree, Anne H Cross, Eva Kubala Havrdova, Ludwig Kappos, Olaf Stuve, Heinz Wiendl, Jerry S Wolinsky, Frank Dahlke, Claire Le Bolay, Li Shen Loo, Sathej Gopalakrishnan, Yann Hyver |
|
2024-10-17 |
[Comment] Trial designs for motor neuron disease in the 21st century |
Steve Vucic |
|
2024-10-17 |
[Comment] Evobrutinib in multiple sclerosis: challenges and unmet goals |
Anneke van der Walt |
|
2024-10-17 |
[Correspondence] Equitable access to levetiracetam for people with epilepsy |
Arjune Sen, Neerja Chowdhary, Asma Hallab, Michele Romoli, J Helen Cross, Bernadette Cappello |
|
2024-10-17 |
[Personal View] Frailty for neurologists: perspectives on how frailty influences care planning |
Marco Canevelli, Caitlin Jackson-Tarlton, Kenneth Rockwood |
|
2024-10-17 |
[Comment] Looking beyond the neurological diagnosis: considering frailty |
A Jon Stoessl |
|
2024-10-17 |
[In Context] Learning to be an adult with a disability |
Jules Morgan |
|
2024-10-17 |
[In Context] On how a brain beholds beauty |
Rui Araújo |
|
2024-09-19 |
[Correspondence] Considerations for future trials in cerebral cavernous malformations |
Ali M Alawieh, Hassan Saad, Jonathan A Grossberg, Daniel L Barrow |
|
2024-09-19 |
[Correspondence] Considerations for future trials in cerebral cavernous malformations |
Marco Cenzato, Ulrich Sure, Giuseppe Lanzino, Davide Boeris, Torstein Meling, Luca Regli, Andreas Gruber, Peter Vajkoczy, Michael Lawton |
|
2024-09-19 |
[Correspondence] RAB32 mutation in Parkinson's disease |
Yuwen Zhao, Hongxu Pan, Jifeng Guo, Beisha Tang, Zhenhua Liu |
|
2024-09-19 |
[Correspondence] RAB32 mutation in Parkinson's disease – Author's reply |
Matthew J Farrer |
|
2024-09-19 |
[Correspondence] RAB32 mutation in Parkinson's disease |
Edoardo Monfrini, Raffaella Minardi, Franco Valzania, Giovanna Calandra-Buonaura, Paola Mandich, Alessio Di Fonzo, ParkNet Study Group |
|
2024-09-19 |
[Correspondence] RAB32 mutation in Parkinson's disease |
Pilar Gómez-Garre, Miguel Martín-Bórnez, Pablo Mir |
|
2024-09-19 |
[Comment] Diagnosis of multiple sclerosis: challenges and opportunities |
Mitchell Wallin |
|
2024-09-19 |
[Correspondence] RAB32 mutation in Parkinson's disease |
Christian Beetz, Mandy Radefeldt, Kornelia Tripolszki, Krishna Kumar Kandaswamy, Peter Bauer, ROPAD Study Group |
|
2024-09-19 |
[Comment] Amyloid removal and the appearance of brain volume loss |
Bradley T Hyman |
|
2024-09-19 |
[Comment] Targeting auto-antibodies for CIDP: hope and questions |
Yusuf A Rajabally |
|
2024-09-19 |
[Comment] Important considerations for children with non-dystrophic myotonia |
Bettina C Henzi, Andrea Klein |
|
2024-09-19 |
[Comment] Global burden of stroke: dynamic estimates to inform action |
Simiao Wu, Ming Liu |
|
2024-09-19 |
[Correspondence] Considerations for future trials in cerebral cavernous malformations – Authors' reply |
CARE pilot trial collaboration |
|
2024-09-19 |
[Personal View] Differential diagnosis of suspected multiple sclerosis: considerations in people from minority ethnic and racial backgrounds in North America, northern Europe, and Australasia |
Lilyana Amezcua, Dalia Rotstein, Afsaneh Shirani, Olga Ciccarelli, Daniel Ontaneda, Melinda Magyari, Victor Rivera, Dorlan Kimbrough, Ruth Dobson, Bruce Taylor, Mitzi Williams, Ruth Ann Marrie, Brenda Banwell, Bernhard Hemmer, Scott D Newsome, Jeffrey A C |
|
2024-09-19 |
[Personal View] Differential diagnosis of suspected multiple sclerosis: global health considerations |
Jorge Correale, Andrew J Solomon, Jeffrey A Cohen, Brenda L Banwell, Fernando Gracia, Tirisham V Gyang, Fernando Hamuy Diaz de Bedoya, Mary P Harnegie, Bernhard Hemmer, Anu Jacob, Ho Jin Kim, Ruth Ann Marrie, Farrah J Mateen, Scott D Newsome, Lekha Pandit |
|
2024-09-19 |
[Editorial] Improving access to medicines for neurological disorders |
The Lancet Neurology |
|
2024-09-19 |
[Articles] Safety, tolerability, and efficacy of subcutaneous efgartigimod in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ADHERE): a multicentre, randomised-withdrawal, double-blind, placebo-controlled, phase 2 trial |
Jeffrey A Allen, Jie Lin, Ivana Basta, Tina Dysgaard, Christian Eggers, Jeffrey T Guptill, Kelly G Gwathmey, Channa Hewamadduma, Erik Hofman, Yessar M Hussain, Satoshi Kuwabara, Gwendal Le Masson, Frank Leypoldt, Ting Chang, Marta Lipowska, Murray Lowe, G |
|
2024-09-19 |
[Personal View] Brain volume change following anti-amyloid β immunotherapy for Alzheimer's disease: amyloid-removal-related pseudo-atrophy |
Christopher R S Belder, Delphine Boche, James A R Nicoll, Zane Jaunmuktane, Henrik Zetterberg, Jonathan M Schott, Frederik Barkhof, Nick C Fox |
|
2024-09-19 |
[Articles] Global, regional, and national burden of stroke and its risk factors, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021 |
GBD 2021 Stroke Risk Factor Collaborators |
|
2024-09-19 |
[Articles] Mexiletine versus lamotrigine in non-dystrophic myotonias: a randomised, double-blind, head-to-head, crossover, non-inferiority, phase 3 trial |
Vinojini Vivekanandam, Iwona Skorupinska, Dipa L Jayaseelan, Emma Matthews, Richard J Barohn, Michael P McDermott, Michael G Hanna |
|
2024-09-19 |
[In Context] Navigating the roads ahead for Alzheimer's disease |
Robert Stirrups |
|
2024-09-19 |
[In Context] On the trail of Edinburgh's neuroscience past and present |
Peter Ranscombe |
|
2024-09-19 |
[In Context] Non-inferiority design for trials in multiple sclerosis |
Maria Pia Sormani, Heinz Wiendl |
|
2024-09-19 |
[In Context] Shaida Khan |
|
|
2024-09-19 |
[In Context] Health as a philosophical idea |
Carlos M Madrid-Casado |
|
2024-09-19 |
[In Context] Christopher Ross: diseases of the brain, not the mind |
Ray Cavanaugh |
|
2024-09-19 |
[Correspondence] The Yaoundé Declaration |
Alfred K Njamnshi, Agustin Ibanez, Gagandeep Singh, Mika Pyykko, Vladimir Hachinski, Harris A Eyre, Scientific Technical Committee |
|
2024-08-15 |
[Review] Intracranial pressure monitoring in adult patients with traumatic brain injury: challenges and innovations |
Tommaso Zoerle, Erta Beqiri, Cecilia A I Åkerlund, Guoyi Gao, Thomas Heldt, Gregory W J Hawryluk, Nino Stocchetti |
|
2024-08-15 |
[Editorial] The evolving paradigm of Alzheimer's disease diagnosis |
The Lancet Neurology |
|
2024-08-15 |
[Articles] Safety and efficacy of intra-erythrocyte dexamethasone sodium phosphate in children with ataxia telangiectasia (ATTeST): a multicentre, randomised, double-blind, placebo-controlled phase 3 trial |
Stefan Zielen, Thomas Crawford, Luca Benatti, Mauro Magnani, Matthias Kieslich, Monique Ryan, Isabelle Meyts, Sheffali Gulati, Rupam Borgohain, Ravi Yadav, Pramod Pal, Anaita Hegde, Suresh Kumar, Anand Venkateswar, Vrajesh Udani, Kollencheri P Vinayan, An |
|
2024-08-15 |
[Correspondence] Ageing and dementia in India |
Thomas Gregor Issac |
|
2024-08-15 |
[In Context] Globally advancing neurological education in headache |
Daniele Martinelli, Massimo Leone, Rami Burstein, Augustina Charway-Felli, Cristina Tassorelli |
|
2024-08-15 |
[Corrections] Correction to Lancet Neurol 2024; 23: 852–53 |
|
|
2024-08-15 |
[In Context] Angela Dos Santos |
|
|
2024-08-15 |
[In Context] Lenin's cause of death |
Antonio Perciaccante, Saudamini Deo, Andreas G Nerlich, Philippe Charlier, Raffaella Bianucci |
|
2024-08-15 |
[In Context] Parkinson's disease is not just a tremor |
Jules Morgan |
|
2024-08-15 |
[In Context] Andrew Singleton: from small island to “Disneyland for doctors” |
Udani Samarasekera |
|
2024-08-15 |
[Correspondence] A proposal for equity neuroscience |
Bruce Ovbiagele |
|
2024-08-15 |
[Comment] Lessons from the ATTeST trial in ataxia telangiectasia |
Yuka Koike, Osamu Onodera |
|
2024-08-15 |
[Correspondence] A biobank for Parkinson's disease and atypical parkinsonism in central Asian and Transcaucasian regions |
Central Asian and Transcaucasian Parkinson's Disease Consortium, Rauan Kaiyrzhanov |
|
2024-08-15 |
[Correspondence] Pragmatic outcomes for stroke research |
Johanna M Ospel, Aravind Ganesh, Mayank Goyal |
|